A share price of Compass Therapeutics Inc [CMPX] is currently trading at $5.71, up 0.18%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CMPX shares have gain 9.60% over the last week, with a monthly amount glided 15.12%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Citizens JMP started tracking the stock with Mkt Outperform rating on December 03, 2025, and set its price target to $10. On December 03, 2025, Cantor Fitzgerald initiated with a Overweight rating. Canaccord Genuity started tracking the stock assigning a Buy rating and suggested a price target of $10 on December 03, 2025. Leerink Partners upgraded its rating to Outperform for this stock on April 02, 2025, but kept the price target unchanged to $6. In a note dated February 24, 2025, Guggenheim initiated an Buy rating and provided a target price of $12 on this stock.
Compass Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.33 and $6.25. Currently, Wall Street analysts expect the stock to reach $9.67 within the next 12 months. Compass Therapeutics Inc [NASDAQ: CMPX] shares were valued at $5.71 at the most recent close of the market. An investor can expect a potential return of 69.35% based on the average CMPX price forecast.
Analyzing the CMPX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.49 and Total Capital is -0.33. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Compass Therapeutics Inc [NASDAQ:CMPX] is 17.82. Further, the Quick Ratio stands at 17.82, while the Cash Ratio is 3.72.
Transactions by insiders
Recent insider trading involved Schuetz Thomas J., CHIEF EXECUTIVE OFFICER, that happened on May 27 ’25 when 10000.0 shares were purchased. Director, GORDON CARL L completed a deal on Apr 09 ’25 to sell 3.57 million shares. Meanwhile, Director ORBIMED ADVISORS LLC sold 3.57 million shares on Apr 09 ’25.
